Respiratory bacterial infections cause mild to severe diseases worldwide, such as pharyngitis, sinusitis, bronchitis, bronchiolitis and pneumonia, which are associated with huge costs for society.
Relevant human models are mandatory to test new molecules for shortening and alleviating these diseases, or to develop new therapies.
MucilAir™ and SmallAir™ hold in vitro specific mechanisms to counter invaders comparable to the in vivo situation, such as mucus production, mucociliary clearance, and secretion of defensive molecules.